Investors have recently focused on the NCE status for Amarin's (NASDAQ: AMRN) triglyceride-lowering drug Vascepa and potential suitors for the company, but many might be overlooking a topic that is essential to the future of this biotech stock: patents.
A cascade of patents protecting Vascepa from generic competitors has been rolling in lately, and Amarin is keen on obtaining more IP for its flagship product. In this video, health-care analysts Max Macaluso and Brenton Flynn talk about the drug's latest patents, and discuss why they are so vital for Amarin today.